跳至主要内容
临床试验/EUCTR2009-014049-10-FR
EUCTR2009-014049-10-FR进行中(未招募)1 期

Exploratory study of besipirdine efficacy and safety in male patients with persistent stress urinary incontinence after radical prostatectomy

Institut de Recherche Pierre Fabre0 个研究点目标入组 25 人开始时间: 2009年10月8日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • - Male out patients,
  • - Aged =40 and = 80 years,
  • - Stress urinary incontinence following radical prostatectomy (for prostate cancer) persistent for at least 12 months and stable for at least 6 months prior to selection visit,
  • - Using pads for Stress Urinary Incontinence,
  • - Pad weight between 10 and 75 g at 24-hour home Pad Test (average weight of the 24-hour home pad test performed for 3 consecutive days within the 7 days prior to the inclusion visit),
  • - Life expectancy of at least 6 months
  • - Having signed his informed consent form,
  • - Patient able to fill in self-questionnaires,
  • - Affiliated to a social security system, or is a beneficiary
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Mixed incontinence with predominant Overactive Bladder
  • - Urinary incontinence prior to prostatectomy,
  • - Neurological pathology that affects the lower urinary tract (Spinal cord lesions, multiple sclerosis, Parkinson’s disease, Diabetes Mellitus ….),
  • - Adult nocturnal enuresis,
  • - Recent urethral pathology (<6 months) such as fistula, diverticulosis, stenosis,
  • - Recent radiotherapy (<6 months)
  • - Absence of voluntary micturition (permanent leakage),
  • - Polyuria (urinary volume > 3 l/day),
  • - Recurrent urinary infection (every 6 months or less),
  • - Perineal reeducation on-going or stopped less than 3 months prior to selection,
  • - Bad compliance in patient diary completion during the run-in period (i.e. data reported less than 3 consecutive days),
  • - Bradycardia (resting HR<50 bpm),
  • - Arterial Hypertension (defined as SBP>140 mmHg and/or DBP>90 mmHg or uncontrolled and not stable),
  • - Any clinically significant cardiac arrhythmia or conduction disturbance,
  • - Evidence of active liver disease (levels of AST or ALT> 2 times the upper normal laboratory value and/or alkaline phosphatase > 1,5 times the upper normal laboratory value)
  • - Intake of any treatment known to have an activity on urethral sphincter or detrusor (e.g. anticholinergic, antidepressants, a-stimulants…)
  • - Recent start or dosage modification of anti-androgen treatment (< 6 months)
  • - Patient known to be non responder to NSRI,
  • - Bad compliance to study drug intake during the run-in period (i.e. less than 70%),
  • - Alcohol or drug abuse or dependence,
  • - Is a family member or work associate (secretary, nurse, technician,…) of the Investigator,
  • - Has participated in another clinical trial within the last 3 month(s), has received treatment with known remnant effects or undergone investigation liable to interfere with the present clinical trial,
  • - Mentally unable to understand the nature, objectives and possible consequences of the trial; or refusing to subject himself to its constraints,
  • - Has forfeited his freedom by administrative or legal award or is under guardianship.
  • - Known lactose intolerance,

研究者

相似试验